Price$0.23+0.01 (+4.86%)
01:30 PM07:45 PM
News · 26 weeks45+100%
2026-04-192026-10-11
Mix1990d
- SEC Filings13(68%)
- Other6(32%)
Latest news
25 items- SECAmendment: SEC Form 6-K/A filed by Enlivex Ltd.6-K/A - Enlivex Ltd. (0001596812) (Filer)
- SECAmendment: SEC Form 6-K/A filed by Enlivex Ltd.6-K/A - Enlivex Ltd. (0001596812) (Filer)
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Announces Termination of Previously-Announced Financing Payable in RAIN TokensNes-Ziona, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the termination of a securities purchase agreement entered into with the Rain Foundation, pursuant to which the Company had agreed, subject to shareholder approval, to sell and issue to the Rain Foundation in a private placement an aggregate of 66,666,667 of the Company’s ordinary shares, which the investor had elected to purchase using RAIN tokens. The Company terminated the securities purchase agreement in accordance with the Company’s termination rights thereunder; therefore, the Company wil
- SECSEC Form 424B3 filed by Enlivex Ltd.424B3 - Enlivex Ltd. (0001596812) (Filer)
- SECSEC Form EFFECT filed by Enlivex Ltd.EFFECT - Enlivex Ltd. (0001596812) (Filer)
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- SECSEC Form F-3 filed by Enlivex Ltd.F-3 - Enlivex Ltd. (0001596812) (Filer)
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs JuneAs of July 29, 2026, trading volume on the Rain protocol reached $860MM1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the ", Company", )), a quality longevity company powered by a prediction markets treasury, today provided an update on the Rain protocol trading metrics. Trading volume on the Rain protocol reached $860 million, and experienced a substantial increase of 622% between the trading volume of June 2026 vs July 2026. According to the Rain Foundation, the target trading volumes on the protocol are expected to increase substantially to $1.3 billion in
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical MilestonesWebinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including its new RMAT designation from the FDA Nes-Ziona, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or "the Company")), a quality longevity company powered by a prediction markets treasury, today announced that its management team will host a live webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time to provide investors with additional detail on the Company’s recently announced private placement (the "Transaction"), the status and strategy of its RAIN treas
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Announces $400,000,000 Private PlacementNes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or "the Company")), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with a single institutional investor with respect to the private placement of $400,000,000 of ordinary shares (or ordinary share equivalents in lieu thereof) at a price of $5.00 per share for subscription amounts funded in U.S. dollars, USDT or USD Coin and $6.00 per share for subscription amounts funded in RAIN tokens, the $5.00 price representing a premium of 17.4% and the $6.00 price representing a premium of 40.8%, in each case to the c
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion●As of July 18, 2026, net asset value (NAV1) per share was $66.16 ●As of July 18, 2026, Enlivex held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion2. Nes-Ziona, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the ", Company", )), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of July 18, 2026, the net asset value (NAV1) per ordinary share was $66.16, and the Company held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion2. The updated unaudited mark-to-market treasury metrics are publicly available on the Company's
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee OsteoarthritisFDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval. Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that the U.S. Food and Drug Administrati
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026Nes-Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced a 1-for-15 reverse split (the "Reverse Split") of its ordinary shares. Beginning on July 9, 2026, the Company’s ordinary shares will trade on The Nasdaq Capital Market on a split-adjusted basis. As a result of the Reverse Stock Split, every fifteen ordinary shares will automatically be combined into one ordinary share. Upon effectiveness of the Reverse Split, the number of authorized ordinary shares will be ratably reduced from 2,375,000,000 to 158,333,334, and the par value of each ordinary share will ratably increase from NIS 0.40 to
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading VolumeRanked second globally in 24-hour spot trading volume, Gate further extends market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, June 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company"), "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that its primary treasury asset, the RAIN token, is expected to be listed on the Gate cryptocurrency exchange, effective June 24, 2026 at 10:00 AM UTC. The listing represents a continued expansion of RAIN’s exchange infrastructure, increasing its accessibility, global reach, and token liquidity.According to Gate
ENLV FAQ
6 questionsWhat does Enlivex Ltd. do?
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are...Where does ENLV stock trade?
Enlivex Ltd. (ENLV) is listed on NASDAQ.What sector and industry is ENLV in?
Enlivex Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Enlivex Ltd. go public?
Enlivex Ltd. (ENLV) completed its IPO in 2014.What companies are similar to ENLV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ENLV side-by-side with any of them on Quantisnow.How can I track ENLV on Quantisnow?
Quantisnow aggregates Enlivex Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ENLV to receive live email and push alerts on every new disclosure.